Clinical Trials Logo

Rheumatoid Arthritis clinical trials

View clinical trials related to Rheumatoid Arthritis.

Filter by:

NCT ID: NCT00422942 Terminated - Clinical trials for Rheumatoid Arthritis

A Pharmacokinetic and Pharmacodynamic Study of MabThera (Rituximab) Plus Methotrexate in Patients With Rheumatoid Arthritis (RA)

Start date: January 2006
Phase: Phase 2
Study type: Interventional

This single arm study will investigate the pattern of B cell depletion in synovial tissue and peripheral blood of patients with active RA, after MabThera (1000mg iv x 2 on days 1 and 15) + methotrexate (10-25mg/week po) treatment. The clinical efficacy and pharmacokinetic profile of MabThera after treatment and retreatment will also be investigated. The anticipated time on study treatment is 2+ years, and the target sample size is <100 individuals.

NCT ID: NCT00422383 Completed - Clinical trials for Rheumatoid Arthritis

A Study of Retreatment With MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis (RA)

Start date: February 2006
Phase: Phase 3
Study type: Interventional

This study will evaluate the efficacy and safety of various treatment and retreatment regimens of MabThera. All patients will receive concomitant methotrexate, 10-25mg once weekly either orally or parenterally. The anticipated time on study treatment is 2+ years, and the target sample size is 100-500 individuals.

NCT ID: NCT00422227 Completed - Clinical trials for Rheumatoid Arthritis

Study Comparing Etanercept With Usual DMARD Therapy in Subjects With Rheumatoid Arthritis in the Asia Pacific Region

Start date: June 2007
Phase: Phase 4
Study type: Interventional

The purpose of this study is to compare the efficacy of etanercept with usual disease-modifying anti-rheumatic drug (DMARD) therapy in the treatment of moderate to severe rheumatoid arthritis (RA) over 16 weeks in the Asia Pacific region.

NCT ID: NCT00420927 Completed - Clinical trials for Rheumatoid Arthritis

Study of the Optimal Protocol for Methotrexate and Adalimumab Combination Therapy in Early Rheumatoid Arthritis

OPTIMA
Start date: December 2006
Phase: Phase 4
Study type: Interventional

This study compared the safety and efficacy of combination therapy with adalimumab plus methotrexate (MTX) to that of MTX monotherapy (i.e., placebo plus MTX) in subjects with early rheumatoid arthritis (RA).

NCT ID: NCT00413452 Completed - Clinical trials for Rheumatoid Arthritis

Etanercept SFP in RA Patients

Start date: December 2006
Phase: Phase 3
Study type: Interventional

Purpose of this study is to evaluate the immunogenicity and overall safety of etanercept SFP therapy administered once weekly for 24 weeks to subjects with rheumatoid arthritis.

NCT ID: NCT00412399 Completed - Clinical trials for Rheumatoid Arthritis

Job Adaptation in Patients With Rheumatoid Arthritis

Start date: June 1999
Phase: N/A
Study type: Observational

The specific aim of this study is to compare the rate of negative work role events in individuals with rheumatoid arthritis compared to healthy controls.

NCT ID: NCT00412256 Completed - Clinical trials for Rheumatoid Arthritis

Omegaven in Patients With Rheumatoid Arthritis (ORA-Trial)

Start date: September 2004
Phase: Phase 3
Study type: Interventional

The primary hypothesis constitutes that the fish-oil preparation (Omegaven) is superior to the preparation based on Soja-oil (Lipovenös)to reduce signs and symptoms in patients with active rheumatoid arthritis.

NCT ID: NCT00411424 Completed - Clinical trials for Rheumatoid Arthritis

Safety, Tolerability and Efficacy Study of the New Medication ASK8007 to Treat Patients With Rheumatoid Arthritis

Start date: September 2007
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to investigate the safety and tolerability of the new medication ASK8007, and to study whether it has a beneficial effect on joint inflammation in patients with rheumatoid arthritis.

NCT ID: NCT00409838 Completed - Clinical trials for Rheumatoid Arthritis

A Phase III Study of Abatacept in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate

Start date: April 2007
Phase: Phase 3
Study type: Interventional

The purpose of the study is to demonstrate the clinical efficacy of abatacept (body-weight tiered dose approximating 10 mg/kg) compared with placebo on a background of methotrexate after 6 months (Day 169) of treatment in Korean patients with active rheumatoid arthritis and an inadequate clinical response to methotrexate

NCT ID: NCT00406419 Terminated - Clinical trials for Rheumatoid Arthritis

A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Continuing Methotrexate Treatment (STAGE)

STAGE
Start date: December 27, 2006
Phase: Phase 3
Study type: Interventional

This study will evaluate the efficacy and safety of ocrelizumab, compared with placebo, in combination with methotrexate in patients with active rheumatoid arthritis who have had an inadequate response to methotrexate. Patients will be randomized to receive placebo, 200mg of intravenous ocrelizumab or 500mg of i.v. ocrelizumab on Days 1 and 15. A repeat course of i.v. treatment will be administered at Weeks 24 and 26. All patients will receive 7.5mg - 25mg/week concomitant methotrexate at a stable dose. The anticipated time on study treatment is 1-2 years. Target sample size is 1000.